Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$0.11 - $0.22 $3,584 - $7,168
32,582 Added 202.83%
48,646 $5,000
Q3 2023

Nov 14, 2023

BUY
$0.11 - $1.76 $1,767 - $28,272
16,064 New
16,064 $2,000

Others Institutions Holding ARAV

About Aravive, Inc.


  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Baader Bank Aktiengesellschaft Portfolio

Follow Baader Bank Aktiengesellschaft and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baader Bank Aktiengesellschaft, based on Form 13F filings with the SEC.

News

Stay updated on Baader Bank Aktiengesellschaft with notifications on news.